Cannabinoid CB 1 receptors in the cerebellum mediate the inhibitory effects of ⌬ 9 -tetrahydrocannabinol (THC) on motor coordination. Intracellular effects of CB 1 receptors include inhibition of adenylyl cyclase via activation of G i/o proteins. There is evidence for the convergence of other neuronal receptors, such as adenosine A 1 and GABA B , with the cannabinoid system on this signaling pathway to influence motor function. Previous studies have shown that brain CB 1 receptors are desensitized and down-regulated by long-term THC treatment, but few studies have examined the effects of long-term THC treatment on downstream effector activity in brain. Therefore, these studies examined the relationship between CB 1 , adenosine A 1 , and GABA B receptors in cerebella of mice undergoing prolonged treatment with vehicle or THC at the level of G protein activation and adenylyl cyclase inhibition. In control cerebella, CB 1 receptors produced less than additive inhibition of adenylyl cyclase with GABA B and A 1 receptors, indicating that these receptors are localized on overlapping populations of cells. Long-term THC treatment produced CB 1 receptor down-regulation and desensitization of both cannabinoid agonist-stimulated G protein activation and inhibition of forskolin-stimulated adenylyl cyclase. However, G protein activation by GABA B or A 1 receptors was unaffected. It is noteworthy that heterologous attenuation of GABA B and A 1 receptor-mediated inhibition of adenylyl cyclase was observed, even though absolute levels of basal and forskolin-or G s -stimulated activity were unchanged. These results indicate that long-term THC administration produces a disruption of inhibitory receptor control of cerebellar adenylyl cyclase and suggest a potential mechanism of cross-tolerance to the motor incoordinating effects of cannabinoid, GABA B , and A 1 agonists.
synaptically inhibit the release of glutamate from parallel fibers (Takahashi et al., 1995; Takahashi and Linden, 2000) . Moreover, because granule cells are the most abundant neuronal cell type in cerebellum, a major portion of the adenylyl cyclase signal in cerebellar preparations probably results from granule cells. The functional significance of convergent signaling has been demonstrated in studies showing interactions between A 1 and CB 1 or GABA B agonists on cerebellarmediated motor incoordination (Dar, 1996 (Dar, , 2000 .
Long-term administration of cannabinoid agonists produces tolerance to cannabinoid-mediated behaviors (Fan et al., 1994) and dependence, which is characterized by antagonist-precipitated withdrawal (Tsou et al., 1995) . In the central nervous system, cellular adaptations to long-term cannabinoid administration include decreased CB 1 receptor levels (down-regulation) and desensitization of CB 1 receptormediated G protein activation in most CB 1 receptor-containing brain regions, including cerebellum (Fan et al., 1996; Sim et al., 1996; Sim-Selley and Martin, 2002) . The mechanism of this desensitization, or decrement in CB 1 receptor signaling, is currently unclear; however, it is thought to result from a combination of CB 1 receptor down-regulation and uncoupling of CB 1 receptors from G proteins. It is noteworthy that desensitization of CB 1 receptor-mediated inhibition of adenylyl cyclase has not yet been demonstrated in brain (Fan et al., 1996) , despite the finding that desensitization of CB 1 -mediated inhibition of adenylyl cyclase occurs after long-term cannabinoid treatment in cell culture models (Dill and Howlett, 1988; Rhee et al., 2000) . Moreover, recent studies have shown that basal and forskolin-and Ca 2ϩ -stimulated adenylyl cyclase activity increase in cerebellum during CB 1 antagonist-precipitated withdrawal (Hutcheson et al., 1998; Tzavara et al., 2000) . Similar findings have been reported in cell culture models, which further demonstrated that this "superactivation" of forskolin-stimulated adenylyl cyclase activity by long-term treatment with cannabinoids depends on the specific adenylyl cyclase isoform expressed in the cell (Rhee et al., 2000) . These findings suggest that the regulation of cerebellar adenylyl cyclase activity by long-term treatment with cannabinoids is partly a function of the predominant adenylyl cyclase types expressed in cerebellar granule cells. Another factor that might affect the regulation of cerebellar adenylyl cyclase activity by long-term treatment with cannabinoids is convergent regulation by multiple receptors, such as A 1 adenosine or GABA B . Long-term administration of A 1 adenosine or GABA B agonists produces desensitization of their respective receptors (Vendite et al., 1998; Wetherington and Lambert, 2002a,b) , and heterologous desensitization of A 1 receptor-mediated effector activity by GABA B agonists has also been observed in cultured neurons (Wetherington and Lambert, 2002a,b) . In contrast, long-term THC treatment did not produce heterologous desensitization of GABA B or A 1 receptor-mediated G protein activation in the brain (Sim et al., 1996; Breivogel et al., 1999) . Nonetheless, DeSanty and Dar (2001) reported that long-term treatment with either CB 1 or A 1 agonist produced cross-tolerance to agonists for both CB 1 and A 1 receptors in a motor incoordination paradigm, suggesting that cerebellar A 1 receptor signaling might be altered downstream of receptor-G protein coupling after long-term THC administration.
The focus of the present investigation was to further examine the regulation of cerebellar adenylyl cyclase activity by CB 1 and other G i/o -coupled receptors, with an emphasis on the response of this effector system to long-term administration of THC. These studies used a THC administration paradigm in mice, whereby the dose was escalated over a 15-day period to produce a maximal level of tolerance to the behavioral effects of THC and a high level of adaptation in CB 1 receptor signaling throughout the brain (Sim-Selley and Martin, 2002) . This paradigm avoids overt behavioral or physiological toxicity, because each dose is administered for 3 days, allowing tolerance to develop before the dose is increased again. The specific goals of this study were to determine whether 1) CB 1 , GABA B , and A 1 receptors converge on overlapping populations of G proteins or adenylyl cyclase in cerebellum; 2) long-term THC treatment desensitizes CB 1 receptor-mediated inhibition of adenylyl cyclase in cerebellum; and 3) long-term THC treatment produces heterologous desensitization of A 1 -or GABA B -mediated inhibition of cerebellar adenylyl cyclase. Long-Term THC Administration. THC was dissolved in a 1:1:18 solution of ethanol, Emulphor, and saline. Mice received subcutaneous injections of THC or vehicle twice daily (7:00 AM and 3:00 PM) for 15 days. THC was initially administered at a dose of 10 mg/kg, and the dose was doubled every 3 days to a final dose of 160 mg/kg. Animals were observed for overt signs of physiological or behavioral toxicity of THC or its vehicle throughout the 15-day treatment period, and none were detected. Twenty-four hours after the final injection, mice were sacrificed by decapitation, and cerebella were dissected on ice and stored individually at Ϫ80°C until assay.
Materials and Methods

Materials
Membrane Preparation. The entire cerebellum of each animal was homogenized in approximately 10 volumes of 50 mM Tris-HCl, 3 mM MgCl 2 , and 1 mM EGTA, pH 7.4 (membrane buffer), with 20 strokes from a glass homogenizer at 4°C. The homogenate was centrifuged at 48,000g at 4°C for 10 min, resuspended in 30 ml of membrane buffer, centrifuged again at 48,000g at 4°C for 10 min, and finally resuspended in 50 mM Tris-HCl, 3 mM MgCl 2 , 0.2 mM EGTA, and 100 mM NaCl, pH 7.4 (assay buffer). Membrane protein levels were determined by the method of Bradford using BSA as the standard.
[ 35 S]GTP␥S Binding. Membranes (5-10 g of protein) were preincubated for 10 min at 30°C with adenosine deaminase (3 mU/ml) in assay buffer. Membranes were then incubated for 2 h at 30°C in assay buffer containing 0.1 nM [
35 S]GTP␥S, 20 M GDP, and adenosine deaminase (3 mU/ml) with and without the indicated concentrations of each agonist. Nonspecific binding was measured with 20 M GTP␥S. Under these conditions, bound [
35 S]GTP␥S was generally within 15% of the total amount of added [
35 S]GTP␥S in each sample. The incubation was terminated by filtration through GF/B glass fiber filters, followed by 3 washes with 3 ml of ice-cold 50 mM Tris-HCl, pH 7.4. Bound radioactivity was determined by liquid scintillation spectrophotometry after overnight extraction of the filters in Econo-1 scintillation fluid.
Adenylyl Cyclase Assay. Membranes (5-25 g of protein) were preincubated with adenosine deaminase as described above and then incubated for 15 min at 30°C in the presence or absence of 1 M forskolin, with or without various drugs at the indicated concentrations, in assay buffer containing 50 M ATP, [␣- 32 P]ATP (1.5 Ci), 0.2 mM dithiothreitol, 0.01% BSA, 50 M cAMP, 50 M GTP, 0.2 mM papaverine, 5 mM phosphocreatine, and 20 U/ml creatine phosphokinase in a final volume of 100 l. Under these conditions, total [␣- 32 P]cAMP recovered was generally less than 1% of the total amount of added [␣- 32 P]ATP in each sample. The reaction was terminated by boiling for 3 min. [
32 P]cAMP was isolated by the dual column (Dowex and alumina) method of Salomon (1979) . [
3 H]cAMP (10,000 dpm) was added to each tube before column chromatography as an internal standard. Radioactivity was determined by liquid scintillation spectrophotometry (45% efficiency for 3 H) after 4.5 ml of the eluate was dissolved in 14. S]GTP␥S binding is defined as actual stimulation by a combination of agonists/(theoretical additive stimulation Ϫ the actual stimulation of the single agonist producing the greatest stimulation alone) ϫ 100%. Net forskolin-stimulated adenylyl cyclase activity is defined as forskolin-stimulated activity Ϫ basal activity (picomoles per milligram per minute). The percentage of inhibition of forskolinstimulated adenylyl cyclase activity is defined as (net forskolinstimulated activity in the absence of agonist Ϫ net forskolin-stimulated activity in the presence of agonist/net forskolin-stimulated activity in the absence of agonist) ϫ 100%. Theoretically additive adenylyl cyclase inhibition is defined as the summation of the percentage of inhibition of net forskolin-stimulated activity by individual drug treatments; actual adenylyl cyclase inhibition is defined as the percentage of inhibition by the combination of agonists. The percentage of additivity of [ 32 P]cAMP production is defined as (actual inhibition of forskolin-stimulated [ 32 P]cAMP production/theoretically additive inhibition of forskolin-stimulated [ 32 P]cAMP production -the actual inhibition of the single agonist producing the greatest inhibition alone). All curve-fitting and statistical analyses were performed using JMP (SAS Institute, Cary, NC). Concentration-effect curves were analyzed by iterative nonlinear regression to obtain EC 50 and E max values. Statistical significance of the data were determined by analysis of variance, followed by the nonpaired twotailed Student's t test, with the following exceptions. The nonpaired two-tailed Student's t test with Bonferroni adjustment was used to determine whether the percentage of additivity was significantly different from 100%. Because the magnitude of EC 50 values varied among different agonists, significant differences between pairs of EC 50 values (vehicle versus THC) were determined by direct comparison with the nonpaired two-tailed Student's t test.
Results
Convergence of Signal Transduction between CB 1 , GABA B , and A 1 Adenosine Receptors
Convergence of G Protein Activation. Additivity experiments were performed to determine whether CB1 receptors converge on the same pools of G proteins that are also activated by GABA B and adenosine A 1 receptors in the cerebellum. Evidence for convergent regulation of signal transduction by these receptors was obtained by determining whether the signal transduction responses were additive or less than additive when agonists for the respective receptors were assessed together or separately in the reaction mixture. WIN 55,212-2 was used to active CB 1 receptors, whereas baclofen and PIA were used to activate GABA B and adenosine A 1 receptors, respectively. Maximally effective concentrations of each agonist were determined in concentrationeffect curves for stimulation of [
35 S]GTP␥S binding (data not shown).
To determine whether cerebellar CB 1 receptors activate common populations of G proteins as GABA B combination was greater than with each agonist alone, this activity seemed to be slightly less than additive compared with the sum of individual agonist-stimulated activities, expressed as theoretical additive stimulation. However, because of normal interexperimental variability in the netstimulated [
35 S]GTP␥S binding data, statistical analysis showed that only the WIN 55,212-2 ϩ baclofen ϩ PIA combination produced significantly less than theoretically additive stimulation.
To more accurately quantify whether each drug combination produced stimulation that was less than additive, the data were calculated as percentage of additivity (Fig. 2B ). This calculation determined the relative additivity of each drug combination compared with the theoretical additive value within each experiment, defined as follows: (net stimulation by drug combination Ϫ net stimulation by the drug that produced the greatest stimulation alone)/(sum of net stimulation by each drug alone Ϫ net stimulation by the drug that produced the greatest stimulation alone) ϫ 100%. According to this calculation, if there is complete overlap of activated G proteins between two receptors, the stimulation produced by any drug combination would equal the stimulation produced by the receptor that produced the greatest stimulation on its own, and this value would be defined as 0% additivity. On the other hand, if the stimulation produced by any receptor combination equals the sum of the net picomoles per milligram stimulated by the individual drugs, the percentage of additivity value would equal 100%. The results showed that all drug combinations exhibited partial additivity, ranging from approximately 64 to 88%. The WIN 55,212-2 ϩ PIA, PIA ϩ baclofen, and three-drug combination were all significantly less than additive, but the WIN 55,212-2 ϩ baclofen combination was not statistically less than 100% additive. Thus, both CB 1 and GABA B receptors produced less than additive stimulation of G protein activation with A 1 receptors but not with each other. These results indicate that CB 1 and GABA B receptors partially converge with adenosine A 1 receptors on a common population of G proteins, which suggests at least partial colocalization of A 1 receptors on the same cells with CB 1 or GABA B receptors.
To confirm that these additivity results reflected convergent regulation of G proteins by receptors colocalized on the same cell membrane, we tested the hypothesis that receptors in membranes prepared from different cells could produce less than additive activation of G proteins when the membranes were suspended together in the same sample. For this purpose, membranes prepared from Chinese hamster ovary cells heterologously expressing -opioid receptors were homogenized together with membranes from mouse cerebellum, which expresses CB 1 but not -opioid receptors. Results showed that stimulation of G protein activation by WIN 55,212-2 and the full -agonist DAMGO were additive in this mixed membrane preparation. Net stimulation was 0.20 Ϯ 0.02 pmol/mg by WIN 55,212-2, 0.29 Ϯ 0.05 pmol/mg by DAMGO, and 0.47 Ϯ 0.07 pmol/mg by WIN 55,212-2 ϩ DAMGO. The percentage of additivity was 93 Ϯ 6.4%, which was not significantly different from 100%. These results indicate that convergent activation of G proteins by receptors on different populations of cells does not occur to a significant extent, which supports the conclusion that less than additive activation of G proteins by different receptors within the same tissue is suggestive of colocalization on overlapping cell populations.
Convergence of Adenylyl Cyclase Inhibition. To determine whether CB 1 receptors regulate the same population of adenylyl cyclase with GABA B or A 1 receptors in cerebellum, additivity studies of receptor-mediated inhibition of for- skolin-stimulated adenylyl cyclase were performed. Maximally effective concentrations of WIN 55,212-2, baclofen, and PIA, as given above, were confirmed by concentration-effect curves for inhibition of adenylyl cyclase activity (data not shown). In the absence of inhibitory agonist, 1 M forskolin stimulated cAMP synthesis to a rate of 459 Ϯ 2.6 pmol/mg/ min, which was a 2.82 Ϯ 0.14-fold increase over basal activity. All drugs and drug combinations tested significantly inhibited forskolin-stimulated adenylyl cyclase activity but did not affect the basal activity of the enzyme (data not shown). Net inhibition of forskolin-stimulated activity by each drug alone ranged from 66 Ϯ 12.4 pmol/mg/min (WIN 55,212-2) to 105 Ϯ 7.4 pmol/mg/min (baclofen) (Fig. 2A) , corresponding to approximately 22 to 30% inhibition of net forskolin-stimulated adenylyl cyclase activity (Fig. 2B) .
Each drug combination seemed to produce inhibition of forskolin-stimulated adenylyl cyclase activity (picomoles per milligram per minute) that was less than the theoretical additive inhibition (Fig. 2A) , but statistical analysis showed that only baclofen ϩ PIA and the combination of all three drugs were significantly less than additive. However, because of normal interexperimental variability in the absolute rates of adenylyl cyclase activity, the percentage of inhibition of net forskolin-stimulated activity is a more precise measurement of the effect of each drug and drug combination. The percentage of inhibition of net forskolin-stimulated activity was found to be significantly less than additive for all drug combinations, based on the comparison to the sum of the percentage of inhibition by each drug alone (Fig. 2B) . The percentage of additivity of each drug combination was then calculated for inhibition of adenylyl cyclase using the same relationship described above for G protein activation. The results showed that all drug combinations produced inhibition that was significantly less than 100% additive, with values ranging from 29 to 57% additivity (Fig. 2C) . Thus, in cerebellum, CB 1 receptors produce less than additive inhibition of adenylyl cyclase with GABA B and A 1 adenosine receptors, which also produced less than additive inhibition with each other. These results suggest that there is a high degree of colocalization among these inhibitory receptors and that levels of adenylyl cyclase are a limiting factor relative to activated G proteins in this signal transduction pathway.
Effects of Long-Term THC Administration on Signaling by CB 1 , GABA B , and A 1 Adenosine Receptors
Effects of Long-Term THC on G Protein Activation. Mice were injected twice daily with escalating doses of THC over a 15-day period to induce cannabinoid tolerance. The initial dose of THC was 10 mg/kg, and this dose was doubled every 3rd day up to a final dose of 160 mg/kg. This treatment paradigm has previously been shown to produce a high level of tolerance to THC-mediated antinociception, hypothermia, and hypolocomotion, as well as desensitization and down-regulation of CB 1 receptors throughout the brain, as measured by agonist-stimulated [
35 S]GTP␥S and [ 3 H]SR141716A autoradiography, respectively (Sim-Selley and Martin, 2002) . To determine whether long-term administration of THC altered the ability of CB 1 receptors to activate G proteins in cerebellar membranes, concentration-effect curves of agonist-stimulated [
35 S]GTP␥S binding were conducted with the full CB 1 agonist WIN 55,212-2 and the high-efficacy partial agonist CP 55,940 (Breivogel et al., 1998) . The results (Fig. 3) showed that long-term THC treatment produced an apparent decrease in CB 1 receptor-mediated G protein activation by both drugs; however, this decrease was greater in magnitude with CP 55,940 (Fig. 3B) than with WIN 55,212-2 (Fig. 3A) . Nonlinear regression analysis of the concentration-effect curves supported this conclusion (Table 1) To determine whether long-term administration of THC caused a heterologous desensitization of GABA B and A 1 receptor-mediated G protein activation in cerebellar membranes, concentration-effect curves for stimulation of [ 35 S]GTP␥S binding were conducted with baclofen and PIA, respectively. In contrast to results obtained with CB 1 receptor-mediated G protein activation, there was no effect of long-term THC treatment on the potency or maximal stimulation produced by either baclofen or PIA ( Fig. 4; Table 1 ). Therefore, long-term THC treatment produced homologous desensitization of CB 1 receptormediated G protein activation in cerebellum.
Effects of Long-term THC on Adenylyl Cyclase Inhibition. To determine the effects of long-term THC administration on CB 1 receptor-mediated inhibition of forskolinstimulated adenylyl cyclase activity, concentration-effect curves were generated with WIN 55,212-2, CP 55,940, and the low-efficacy partial agonist THC. Results showed little effect of long-term THC treatment on inhibition of cerebellar adenylyl cyclase by WIN 55,212-2 (Fig. 5A ), but the inhibitory effects of CP 55,940 and THC were both attenuated (Fig.  5, B and C) . Nonlinear regression analysis of the concentration-effect curves (Table 2) showed that, although there was no difference in maximal inhibition by WIN 55,212-2, there was a small but significant increase (1.9-fold) in the EC 50 value of this full agonist in THC-treated mice. Moreover, long-term THC treatment decreased the maximal inhibition by CP 55,940 and THC by 21 and 42%, respectively, relative to the maximal inhibition produced by these drugs in vehicletreated mice. Thus, long-term THC treatment desensitized CB 1 receptor-mediated inhibition of forskolin-stimulated adenylyl cyclase in a manner inversely related to the efficacy of the agonist used to inhibit the enzyme.
To determine whether GABA B and adenosine A 1 receptormediated inhibition of cerebellar adenylyl cyclase was affected by long-term THC administration, concentration-effect curves were conducted with baclofen and PIA, respectively. Long-term THC treatment attenuated the inhibition of adenylyl cyclase by both baclofen and PIA (Fig. 6) , in contrast to results obtained with these drugs in stimulating G protein activation. Nonlinear regression analysis confirmed that maximal inhibition of adenylyl cyclase by both PIA and baclofen was decreased by approximately 18%, and there was a trend toward an increase in the EC 50 value of baclofen (1.8-fold, p ϭ 0.059). Therefore, long-term THC treatment produced an apparent heterologous desensitization of CB 1 , GABA B , and A 1 receptor-mediated inhibition of cerebellar adenylyl cyclase.
This apparent heterologous desensitization could not be explained by changes in the levels of basal and forskolin-or G␣ s -stimulated adenylyl cyclase activity. No significant differences were observed between THC-and vehicle-treated mice in the absolute level of basal and GTP␥S-or forskolinstimulated adenylyl cyclase activity in cerebellar membranes (Fig. 7A) . Moreover, the level of forskolin-stimulated adenylyl cyclase activity, calculated as a percentage of basal activity, was not different between THC-and vehicle-treated mice (301 Ϯ 9.2 versus 308 Ϯ 16%, respectively). Finally, concentration-dependent stimulation of cerebellar adenylyl cyclase activity by the ␤-adrenergic agonist isoproterenol was not different between THC-and vehicle-treated mice (Fig. 7B) .
Discussion
The present study is to our knowledge the first demonstration of long-term cannabinoid-induced desensitization of CB 1 receptor-mediated inhibition of adenylyl cyclase in brain. Previous studies demonstrated desensitization of adenylyl cyclase inhibition in CB 1 receptor-expressing cell lines (Dill and Howlett, 1988 ), but few have examined this question in brain. In one study (Fan et al., 1996) , long-term administration of CP 55,940 produced no change in potency or maximal inhibition of cerebellar adenylyl cyclase by CP 55,940, despite a 50% decrease in the B max value of [ 3 H]CP 55,940 binding. Potential explanations for these discrepant results include differences in treatment duration, dosing regimen, or the particular drug administered. In the present study, ex- posure to escalating doses of THC over 15 days produced desensitization of CB 1 receptor-mediated G protein activation and inhibition of adenylyl cyclase, whereas the previous study examined a constant dose of CP 55,940 for 6.5 days.
One potentially important factor is the difference in intrinsic efficacy between CP 55,940 and THC. We have previously found that long-term treatment with WIN 55,212-2 produced less desensitization than long-term treatment with THC in certain brain regions, including cerebellum (Sim-Selley and Martin, 2002) . In general, previous studies found WIN 55,212-2 to be a full agonist for G protein activation relative to CP 55,940, and both exhibited greater efficacy than THC (Sim et al., 1996; Breivogel et al., 1998) . Thus, there seems to be an inverse relationship between the efficacy of the treatment drug and CB 1 receptor desensitization in brain. The magnitude of desensitization also depended on the intrinsic efficacy of the cannabinoid used in the in vitro assay. Thus, greater desensitization was observed when testing CP 55,940 or THC compared with WIN 55,212-2. This relationship was previously shown for stimulation of G protein activity in cerebellum after long-term THC treatment (Breivogel et al., 2003) , and the present results extend these findings to inhibition of adenylyl cyclase. In this case, CP 55,940 and THC both exhibited decreased maximal inhibition of adenylyl cyclase after long-term THC treatment, whereas WIN 55,212-2 only exhibited decreased potency. This study also examined the interaction between CB 1 , A 1 , and GABA B receptors in cerebellum. In agreement with previous studies (Wojcik et al., 1985; Pacheco et al., 1993) , GABA B receptors exhibited less than additive inhibition of adenylyl cyclase with either CB 1 or adenosine A 1 receptors. A novel finding of the present study is that CB 1 and A 1 receptors produced less than additive regulation of both G protein and adenylyl cyclase activity. The finding that activation of G proteins by a combination of receptors was closer to additive than was inhibition of adenylyl cyclase suggests that adenylyl cyclase is the limiting factor in this signal transduction pathway. A similar conclusion was reached in previous studies comparing G protein and adenylyl cyclase responses (Wojcik et al., 1985; Pacheco et al., 1993) . The finding that cerebellar GABA B and CB 1 receptors produce additive activation of G proteins agrees with a previous report (Pacheco et al., 1993) . However, the finding that G protein activation by GABA B and A 1 receptors was less than additive disagrees with a previous study that reported complete additivity (Wojcik et al., 1985) . There are several potential explanations for this discrepancy, such as pretreatment of membranes with adenosine deaminase in the present study to inactivate endogenous adenosine and provide more accurate measurement of A 1 receptor activity, or the use of mice in this study versus rats in the earlier study. An additional possibility is that the previous study assessed G protein activation by measuring low K m GTPase activity, whereas the present study measured [
35 S]GTP␥S binding. The former method may underestimate convergence, because each G protein may be activated by the receptor multiple times as a result of the G␣ subunit reassociating with the G␤␥ subunit after GTP hydrolysis and becoming available for subsequent activation. In the case of GTP␥S, which is hydrolysis-resistant, activated receptors stimulate the accumulation of GTP␥S-bound G␣ subunits, which are no longer available for reactivation by receptors. Thus, agonist-stimulated [
35 S]GTP␥S binding might be more likely to reveal convergent activation of a finite population of G proteins by multiple receptors as a less than additive response.
Convergent signaling by CB 1 , A 1 , and GABA B receptors in the cerebellum could have functional implications for the actions of psychoactive drugs. Studies by Dar and colleagues have documented a synergistic effect of A 1 receptor activation with cannabinoid-induced motor incoordination (Dar, 2000; DeSanty and Dar, 2001) , whereby adenosine agonists and transport inhibitors synergistically enhanced the effects of cannabinoids in an A 1 antagonist-reversible manner. Another potential drug interaction could occur between cannabinoids and ethanol, because ethanol affects A 1 , GABA B , and CB 1 receptor systems (Colombo et al., 2000; Dunwiddie and Masino, 2001; Basavarajappa and Hungund, 2002) and has direct actions on cerebellar adenylyl cyclase via modulation of protein phosphorylation cascades (Tabakoff et al., 2001 ). In fact, behavioral studies have shown interactions between THC/ethanol and baclofen/ethanol in motor incoordination and modulation of these effects by A 1 agonists (Dar, 1996; Dar, 2000) . Attenuation of these motor effects by pertussis toxin implicated interactions at the level of receptor-coupled G protein activity, and direct evidence for a role of adenylyl cyclase in adenosine-mediated modulation of ethanol-induced ataxia has been reported (Dar, 1997) . Although the vehicle used in the present study contains ethanol, which might potentially enhance the heterologous effect of longterm THC treatment on GABA B and A 1 receptor signaling, the amount of ethanol administered was pharmacologically inactive and probably inadequate to produce any effect on signal transduction.
The finding that long-term THC administration produced heterologous attenuation of adenylyl cyclase inhibition by cerebellar GABA B and A 1 receptors has potential implications for in vivo cross-tolerance between agonists of these receptors. For example, studies have demonstrated crosstolerance to cannabinoid-induced motor incoordination and its enhancement by A 1 agonists after long-term treatment with agonists of either receptor (DeSanty and Dar, 2001 ). The present results might provide a mechanism for this cross-tolerance and further suggest that long-term treatment with cannabinoid agonists might produce cross-tolerance to the synergistic enhancement of ethanol-induced motor incoordination by either A 1 or GABA B agonists.
There are several possible mechanisms by which heterologous attenuation of adenylyl cyclase inhibition might be produced by long-term THC treatment. Although long-term THC administration produces CB 1 receptor desensitization and down-regulation, this effect cannot explain heterologous desensitization of adenylyl cyclase inhibition by A 1 or GABA B receptors. Indeed, CB 1 receptor-stimulated G protein activity was homologously desensitized by long-term THC treatment in this and previous studies (Sim et al., 1996 ; Breivogel et al., 1999) . One potential explanation for attenuated effector regulation downstream of receptor-G protein coupling is an enhanced interaction of activated G proteins with regulators of G protein signaling (RGS), which accelerate G protein inactivation and modulate effector signaling (De Vries et al., 2000) . At least two types of RGS proteins (RGS 7 and 10) are found in cerebellar granule cells (Gold et al., 1997) , but their involvement in the regulation of cerebellar CB 1 , A 1 , or GABA B receptor signaling is unknown. Another potential mechanism of attenuated inhibition of adenylyl cyclase by G i/o -coupled receptors is alteration in the expression of adenylyl cyclase isotypes that are differentially regulated by G i/o proteins. For example, types II and VII adenylyl cyclase are expressed in cerebellar granule cells (Hellevuo et al., 1996; Mons et al., 1998) . These isotypes are not inhibited by G␣ i but are stimulated by G␤␥ in the presence of activated G␣ s (Simonds, 1999) , and studies in cell models have shown that CB 1 receptors stimulate these two isotypes (Rhee et al., 2000) . The predominant G i -inhibited adenylyl cyclase isotype in cerebellum is probably type I (Hellevuo et al., 1996; Storm et al., 1998) . Thus, a decreased expression ratio of adenylyl cyclase type I to types II or VII could produce an apparent impairment of receptor-mediated inhibition of forskolin-stimulated activity. It is also possible that increased expression of type I adenylyl cyclase itself could produce an apparent heterologous loss of receptor-mediated inhibition, if the increase in this isotype overcame the capacity of inhibitory receptors to modulate its activity. Indeed, increased basal and forskolin-and Ca 2ϩ /calmodulinstimulated adenylyl cyclase activity has been reported in cerebellum after antagonist-precipitated withdrawal after long-term cannabinoid agonist treatment (Hutcheson et al., 1998; Rubino et al., 2000; Tzavara et al., 2000) . Because adenylyl cyclase I is the major Ca 2ϩ -stimulated isotype in cerebellum (Storm et al., 1998) , a significant portion of cannabinoid withdrawal-enhanced adenylyl cyclase activity could be caused by this isotype. Moreover, cannabinoid agonist-induced superactivation of adenylyl cyclase I has been demonstrated in cell culture models (Rhee et al., 2000) . However, no significant increase in basal and forskolin-or G sstimulated adenylyl cyclase activity was observed in the present study. A likely explanation for this difference is that the manifestation of long-term cannabinoid-induced superactivation of adenylyl cyclase requires administration of the CB 1 antagonist SR141716A in both mice (Hutcheson et al., 1998) and cultured cells (Rhee et al., 2000) . The removal of THC does not produce the same result as the administration of SR141716A, possibly because of the inverse agonist properties of this compound (Howlett et al., 2002) . Moreover, because brains were obtained 24 h after the last THC injection in the present study, forskolin-stimulated adenylyl cyclase activity could have been elevated initially but then returned to baseline. Thus, it is unlikely that the apparent heterologous desensitization of CB 1 -, A 1 -, and GABA B -mediated inhibition of adenylyl cyclase was caused by an elevation in adenylyl cyclase activity per se, although these two responses to long-term THC treatment might be related to a common underlying mechanism.
In conclusion, long-term THC administration in mice produced an apparent heterologous desensitization of CB 1 , A 1 , and GABA B receptor-mediated inhibition of cerebellar adenylyl cyclase. This adaptation occurred at a level of signal transduction that is downstream of the receptor-G protein interface and probably occurred in cells in which all three receptors converge on overlapping populations of adenylyl cyclase. These results provide a functional link between cerebellar endocannabinoid, adenosine, and GABA neurotransmitter systems that might explain the synergistic mediation and cross-tolerance in motor incoordination.
